At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- NNC0442-0344 A (drug)
- How long the study runs
- Study runs about 16 months (dates as stated)
- About the drug or intervention
- NNC0442-0344 A — drug: NNC0442-0344 A will be administered orally.
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 18 Years to 64 Years
- Who
- Male
- Number of participants
- 30
- Started
- 2025-10-23
- Last checked
- 2026-09
Plain English Summary
What is this study?
- • Testing a new treatment for haemophilia a
- • Phase1 - 30 participants
- • This study will test how different doses of study medicine (Inno8) work in the bodies of people with haemophilia A
Who can take part?
- • Ages 18 Years to 64 Years
- • Diagnosed with haemophilia a
- • Male only
Where?
- • Birmingham - Queen Elizabeth Hospital, Birmingham - Haemophilia
- • London - Royal Free Hospital - Haemophilia
- • Sheffield - Royal Hallamshire Hospital
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
This study will test how different doses of study medicine (Inno8) work in the bodies of people with haemophilia A. The purpose of the study is to see if Inno8 is safe to use for people with haemophilia A. The study medicine is a new medicine that cannot yet be prescribed by doctors. The study will last for about 11 weeks.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years - 64 Years
- Who can join: Male only
What the study is looking for
- ✓Age 18-64 years (both inclusive) at the time of signing the agreement to take part.
- ✓Body weight greater than or equal to (≥) 45 kilograms (kgs).
- ✓Diagnosis of congenital haemophilia A with factor VIII (FVIII) activity less than or equal to (≤) 15 percentage (%)...
Who cannot take part
- ✗Current or prior exposure to any prophylactic treatment for haemophilia A within 5 half-lives of the medicinal...
- ✗Body mass index ≥30.0 kilogram per square meter (kg/m\^2).
- ✗Increased risk of thrombosis, e.g. known history of personal or first-degree relative(s) with unprovoked deep vein...
- ✗Any clinical signs or established diagnosis of venous or arterial thromboembolic disease.
- ✗Any known coagulation disorders other than haemophilia A.
See the full criteria
Where Is This Study? (3 UK sites)
Queen Elizabeth Hospital, Birmingham - Haemophilia
Birmingham B15 2TH, United Kingdom
Royal Free Hospital - Haemophilia
London NW3 2QG, United Kingdom
Royal Hallamshire Hospital
Sheffield S10 2JF, United Kingdom
How to Get in Touch
Novo Nordisk
Sponsor contactCONTACT
